Tirzepatide (mounjaro) 5mg 10mg 15mg jakisoni

Tirzepatide

Tirzepatide ndi kafukufuku wofufuza kamodzi pa sabata, insulinotropic polypeptide yodalira shuga wapawiri ndi glucagon-ngati peptide-1 receptor agonist yomwe imaphatikiza zochita za ma incretins kukhala molekyulu imodzi.

Tirzepatide Mimics Mahomoni Achilengedwe Omwe Amalimbikitsa Kumva Mokwanira
Tirzepatide imagwira ntchito motsanzira mahomoni a GLP-1 ndi GIP omwe mwachibadwa amatulutsidwa m'matumbo mukatha kudya, zomwe zimapangitsa kuti insulini itulutsidwe.Zimachepetsanso chilakolako cha chakudya pochepetsa nthawi yomwe imatengera m'mimba kutulutsa ndikulumikizana ndi madera muubongo omwe ali ndi ma GLP-1 receptors kuti awonetse kukhuta.

Tirzepatide ndi mankhwala atsopano omwe adavomerezedwa ndi FDA kuchiza matenda amtundu wa 2 mellitus.Chifukwa cha mphamvu zake zochepetsa thupi,tirzepatidekugwiritsidwa ntchito off-label kuchiza kunenepa.Zimagwira ntchito ngati agonist awiri a GLP-1 ndi GIP agonist kuti apititse patsogolo zopindulitsa zomwe zimawonedwa ndi mankhwala a GLP-1 monga semaglutide.Imagwiritsidwa ntchito ngati mankhwala amtundu wachiwiri wa matenda a shuga, ofanana ndi mankhwala a GLP-1, ndipo amaperekedwa ngati jekeseni kamodzi pa sabata.

Tirzepatide ndi cholandilira insulinotropic polypeptide (GIP) chodalira glucose komanso glucagon-ngati peptide-1 (GLP-1) recepto agonist, yomwe ndi yovomerezeka ndi FDA pochiza matenda amtundu wa 2 mellitus.Ndikofunikira kudziwa kuti tirzepatide ndiyosavomerezeka pochiza matenda a shuga 1 ndipo sanaphunzirepo kwa odwala omwe ali ndi kapamba.Tirzepatide ndi GIP receptor ndi GLP-1 receptor agonist, zomwe zimatsogolera kuwongolera bwino kwa glycemic mu mtundu wa 2 matenda a shuga komanso kuchepetsa kwambiri kulemera.

A FDA adavomereza Tirzepatide mu Meyi 2022. Tirzepatide itha kugwiritsidwanso ntchito popanda chizindikiro pochiza kunenepa kwambiri.Imagwiritsidwa ntchito ngati mankhwala amtundu wachiwiri wa matenda a shuga, ofanana ndi mankhwala a GLP-1 monga semaglutide.Ndi mankhwala omwe amabayidwa kamodzi pa sabata okhala ndi kuchuluka kwa mlingo.

Deta yamakono yamakono yasonyeza kuti tirzepatide ndi yabwino kuposa placebo pakukweza hemoglobin A1C.Chiyeso chachipatala cha SURPASS-5 chinasonyeza kuchepa kwa -2.11% kwa hemoglobin A1C pa 5mg pa sabata dosing, poyerekeza ndi -0.86% ndi placebo.Pa mlingo waukulu wa 15 mg pa sabata, tirzepatide inachititsa kuti -2.34% kuchepetsa hemoglobin A1C.Izi zidawonetsedwa patatha milungu 40.Kuchepetsa kulemera kwa 5.4 kg kumawoneka ndi 5mg ya tirzepatide dosing, ndipo kuchepa kwa 10.5 kg kunawonedwa ndi 15 mg dosing.Mgwirizano wodalira mlingo uwu ndi kuchepa thupi ndi wofanana ndi semaglutide, mankhwala wamba a GLP-1 omwe amagwiritsidwa ntchito powongolera kuwonda.

Poyerekeza, tirzepatide yawonetsedwa kuti imagwira ntchito mofanana ndi mankhwala a GLP-1 koma ndi yothandiza kwambiri.Chifukwa cha kuchepa kwake kolemera komanso kusowa kwa chiwopsezo cha chiwindi, ndizothekanso kuchitapo kanthu pochiza matenda a chiwindi amafuta osamwa mowa (NAFLD) komanso.

ZINDIKIRANI

Timatumiza padziko lonse lapansi.
Mukulangizidwa kukaonana ndi dokotala musanagwiritse ntchito mankhwalawa.